This is a routine board resignation with no trading signal. Monitor future filings for appointment of a new director, which could indicate board composition changes but is unlikely to affect near-term stock price.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 23 $13.68entry
- T+1 · 4mo ago −4.46%α −4.56% · $13.07
- T+5 · 4mo ago −3.58%α −4.06% · $13.19
- T+20 · 3mo ago +4.75%α +1.44% · $14.33
- T+60 · 5w ago −28.00%α −32.55% · $9.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Ian T. Clark resigned from the board of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. No reason was given beyond his notice of intention to resign, and no replacement has been named. This is a routine board-level departure with no immediate impact on operations or strategy.
Key Facts
- Ian T. Clark delivered notice of resignation from the board on July 21, 2026, effective July 22, 2026.
- Clark served on the board for over nine years.
- No replacement director has been named in the filing.
- The company thanked Clark for his contributions; no mention of disagreement or conflict.
Financial Impact
No material financial impact from a single director resignation.
Risk Factors
- Loss of board expertise if Clark's departure leaves a gap in relevant experience, though no immediate risk.
- Potential for additional board departures if internal issues exist, though none indicated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-085790 |
| Document: 0001104659-26-085790-index-headers.html | 0001104659-26-085790 |
| Document: 0001104659-26-085790-index.html | 0001104659-26-085790 |
| Document: 0001104659-26-085790.txt | 0001104659-26-085790 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Viewing Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers